Sort   by:  
 Page size 
ProteomicsA structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia
Abstract Mutations activating RAS/RAF/MEK/ERK signaling are associated with poor outcome in acute myeloid leukemia (AML), but therapeutic targeting of this pathway is challenging. Here, we employ a structure-based, dynamic RAS pathway model to successfully predict RAF inhibitor (RAFi) combinations ...
ORGANISM(S): Homo sapiens (Human) 
2026-06-24 | PXD063606 | Pride
Drug combinations Ras-mutant acute myeloid leukemia. Structure-based modelling 
TranscriptomicsNRASG12V mediates leukemia self renewal [RNA-Seq]
Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine mo...
ORGANISM(S): Mus musculus 
2014-11-16 | E-GEOD-49088 | biostudies-arrayexpress
TranscriptomicsNRASG12V mediates leukemia self renewal [Microarray]
Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine mo...
ORGANISM(S): Mus musculus 
2014-11-16 | E-GEOD-49038 | biostudies-arrayexpress
TranscriptomicsLeukemia stem cell-enriched population expresses self-renewal gene-expression signature [RNA-Seq]
Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine mo...
ORGANISM(S): Mus musculus 
2014-11-14 | E-GEOD-63312 | biostudies-arrayexpress
TranscriptomicsNRASG12V mediates self renewal in AML [RNA-Seq]
Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific function of these pathways in AML is unclear. To elucidate the downstream functions of activated NRAS in AML, we employed a murine mo...
ORGANISM(S): Mus musculus 
2014-11-16 | E-GEOD-49087 | biostudies-arrayexpress
TranscriptomicsAcute myeloid leukemia with CEBPA double-mutations harbors in 76.8% of cases concomitant molecular mutations with TET2 and GATA2 alterations demonstrating strong prognostic impact
Acute myeloid leukemia (AML) with CEBPA mutations is determined as provisional entity in the current WHO. A difference in clinical outcome between single- (sm) and double-mutated (dm) cases has been reported, whereupon dm cases were shown to be associated with longer overall survival (OS). The occur...
ORGANISM(S): Homo sapiens 
2013-04-20 | E-GEOD-42064 | biostudies-arrayexpress
TranscriptomicsNRASG12V oncogene mediates self-renewal in acute myelogenous leukemia
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Mus musculus 
2014-11-16 | E-GEOD-49089 | biostudies-arrayexpress
UnknownPhase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
Not available
S-EPMC11852403 | biostudies-literature
UnknownClinico-genomic characterization of RAS-mutant acute myeloid leukemia.
Not available
S-EPMC12886291 | biostudies-literature
GenomicsCombining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia
PRJNA1184160 | ENA
Sort   by:  
 Page size